Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulixertinib + Hydroxychloroquine in MAPK-mutated GI malignancies
NCT05221320Phase 2Terminated
- Sponsor
- BioMed Valley Discoveries
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ulixertinib in cholangiocarcinoma (CCA), pancreatic adenocarcinoma (PDAC), colorectal adenocarcinoma and 4 more (2 arms), sponsored by BioMed Valley Discoveries. Primary endpoints: Overall Response Rate at 24 months, Serious Adverse Events at 24 months and 1 more. Started May 2022; status: terminated.
02
Drugs
ulixertinib
03
Conditions
cholangiocarcinoma (CCA)pancreatic adenocarcinoma (PDAC)colorectal adenocarcinomaesophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05221320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05221320.